Neuphoria Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEUP research report →
Companywww.neuphoriatx.com
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
- CEO
- Spyridon Papapetropoulos
- IPO
- 2021
- Employees
- 8
- HQ
- Burlington, US
Price Chart
Valuation
- Market Cap
- $26.64M
- P/E
- -0.07
- P/S
- -1.70
- P/B
- 0.91
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.95%
- Op Margin
- 7308.31%
- Net Margin
- 2468.88%
- ROE
- -1538.96%
- ROIC
- -1553.34%
Growth & Income
- Revenue
- $15.65M · 0.00%
- Net Income
- $-369,632 · 97.56%
- EPS
- $-0.23 · -130.00%
- Op Income
- $-1,129,091
- FCF YoY
- 626.05%
Performance & Tape
- 52W High
- $21.40
- 52W Low
- $3.65
- 50D MA
- $4.76
- 200D MA
- $6.48
- Beta
- 0.72
- Avg Volume
- 50.30K
Get TickerSpark's AI analysis on NEUP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 20, 26 | Wilson David Ian | other | 8,537 |
| Jan 20, 26 | Davies Peter Miles Winston | other | 8,537 |
| Jan 20, 26 | Fisher Alan | other | 17,073 |
| Jan 20, 26 | Ryan Jane | other | 8,537 |
| Oct 21, 25 | Lynx1 Capital Management LP | buy | 639,110 |
| Oct 21, 25 | Lynx1 Capital Management LP | other | 0 |
| Aug 27, 25 | Papapetropoulos Spyros | other | 34,559 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 27,000 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 270,000 |
| Apr 16, 25 | Davies Peter Miles Winston | other | 6,783 |
Our NEUP Coverage
We haven't published any research on NEUP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NEUP Report →